Exact Mass: 353.0818656
Exact Mass Matches: 353.0818656
Found 52 metabolites which its exact mass value is equals to given mass value 353.0818656,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Pentoxazone
C17H17ClFNO4 (353.08300840000004)
Precursor ion, [M-H]-, is a 37Cl-isotopolog ion.; The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. The sample was injected by direct infusion.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.
2,5-diamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one
2,5-diamino-6-(5-phosphoribosylamino)-4-pyrimidineone is a member of the class of compounds known as pentose phosphates. Pentose phosphates are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups. 2,5-diamino-6-(5-phosphoribosylamino)-4-pyrimidineone is slightly soluble (in water) and a moderately acidic compound (based on its pKa). 2,5-diamino-6-(5-phosphoribosylamino)-4-pyrimidineone can be found in a number of food items such as horned melon, buffalo currant, papaya, and red algae, which makes 2,5-diamino-6-(5-phosphoribosylamino)-4-pyrimidineone a potential biomarker for the consumption of these food products. 2,5-diamino-6-(5-phosphoribosylamino)-4-pyrimidineone exists in E.coli (prokaryote) and yeast (eukaryote).
Rugosinone
C19H15NO6 (353.08993300000003)
2-((4-Methoxy-3-methyl-2-pyridylmethyl)sulfo)-5-trifluoromethyl-1H-benzimidazole
C16H14F3N3OS (353.08096300000005)
Acenocoumarol
C19H15NO6 (353.08993300000003)
Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, XI and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AA - Vitamin k antagonists D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
lansoprazole sulfide
C16H14F3N3OS (353.08096300000005)
lansoprazole sulfide is a metabolite of lansoprazole. Lansoprazole is a proton-pump inhibitor (PPI) which inhibits the stomachs production of gastric acids. It is manufactured by a number of companies worldwide under several brand names. In the United States it was first approved by the Food and Drug Administration (FDA) in 1995. Lansoprazole has been available as a generic drug since Prevacid patent protection expired on November 10, 2009. Since 2009 Lansoprazole has been available over the counter (OTC) in the U.S. (Wikipedia)
2-(O-Tolylcarbamoyl)naphthalen-3-yl 2-chloroacetate
4-(4'-Chlorobenzyloxy)benzyl nicotinate
Syk Inhibitor
C18H15N3O3S (353.0834080000001)
N-(2-Cyanoethyl)-N-(2-thienylmethyl)-N-[3-(trifluoromethyl)phenyl]urea
C16H14F3N3OS (353.08096300000005)
7,8,10-Trimethoxybenzo[f]-1,3-benzodioxolo[6,5,4-cd]indol-5(6H)-one
C19H15NO6 (353.08993300000003)
2,3:9,10-Bis(methylenedioxy)-5,6-dihydro-8H-dibenzo[a,g]quinolizine-1,8-diol
C19H15NO6 (353.08993300000003)
(+/-)-linaresine|(??)-Linaresine|8,9-dimethoxy-6,7-methylenedioxy-12H<1>benzoxepino<2,3,4-ij>isoquinolin-12-ol|linaresinen
C19H15NO6 (353.08993300000003)
adlumidine|bicucculine|D-bicucculine
C19H15NO6 (353.08993300000003)
(S)-Acenocoumarol
C19H15NO6 (353.08993300000003)
The (R)-enantiomer of acenocoumarol. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AA - Vitamin k antagonists A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
2-[1-(4-methoxyphenyl)-4-nitro-3-thiophen-2-ylbutylidene]propanedinitrile
C18H15N3O3S (353.0834080000001)
1-(6-Chloro-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-isopropylidene-beta-D-ribofuranuronamide
4-(Phenylamino)-3-sulfoazobenzene
C18H15N3O3S (353.0834080000001)
2-Methyl-2-propanyl 5-bromo-3-[(dimethylamino)methyl]-1H-pyrrolo[ 2,3-b]pyridine-1-carboxylate
C15H20BrN3O2 (353.07388000000003)
4-CHLORO-2-TRIFLUOROACETYL-6-(TERT-BUTYLDIMETHYLSILYLOXY)ANILINE
3-(4-ACETOXY-PHENYL)-2-(1,3-DIOXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONIC ACID
C19H15NO6 (353.08993300000003)
1-methylsulfanyl-2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]benzimidazole;2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole
C16H14F3N3OS (353.08096300000005)
2,5-diamino-6-(1-D-ribitylamino)pyrimidin-4(3H)-one 5-phosphate(2-)
anthraquinone-2-carboxyate-N-acetylcysteamine
C19H15NO4S (353.0721750000001)
trans-5-O-caffeoyl-D-quinate
A hydroxy monocarboxylic acid anion that is the conjugate base of trans-5-O-caffeoyl-D-quinic acid; major species at pH 7.3.
1-(2,4-Difluorophenyl)-5-[[[methylamino(sulfanylidene)methyl]hydrazinylidene]methyl]-4-pyrazolecarboxylic acid methyl ester
3,4,5-trihydroxy-6-(4-hydroxy-1H-indole-3-carbonyl)oxyoxane-2-carboxylic acid
2,5-diamino-4-hydroxy-6-(5-phosphoribosylamino)pyrimidine
B 823-08
C16H14F3N3OS (353.08096300000005)
Chlorogenate
A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.
2,5-Diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5-phosphate
5-O-Phosphono-beta-D-ribofuranose in which the hydroxy group at position 1 is substituted by the 6-amino group of 2,5,6-triaminopyrimidin-4(3H)-one.
2,5-diamino-6-(1-D-ribitylamino)pyrimidin-4(3H)-one 5-phosphate(2-)
The dianion resulting from the removal of two protons from the phosphate group of 2,5-diamino-6-(1-D-ribitylamino)pyrimidin-4(3H)-one 5-phosphate.
(10s)-10-[(5r)-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3,5,11-trioxatricyclo[7.3.0.0²,⁶]dodeca-1,6,8-trien-12-one
C19H15NO6 (353.08993300000003)
12,14,16-trimethoxy-3,5-dioxa-10-azapentacyclo[9.7.1.0²,⁶.0⁸,¹⁹.0¹³,¹⁸]nonadeca-1(19),2(6),7,9,11,13(18),14,16-octaen-9-ol
C19H15NO6 (353.08993300000003)
(14r)-5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁵,²³.0¹⁶,²⁰]tetracosa-1(24),2(10),3,8,15,20,22-heptaene-3,14-diol
C19H15NO6 (353.08993300000003)
10-{2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-3,5,11-trioxatricyclo[7.3.0.0²,⁶]dodeca-1,6,8-trien-12-one
C19H15NO6 (353.08993300000003)
4-hydroxy-5,17-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.7.1.0³,⁸.0¹⁴,¹⁸]octadeca-1(17),3,5,7,9,14(18),15-heptaene-12,13-dione
C19H15NO6 (353.08993300000003)
(3s,4r,6r,10s)-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,13,15,17(21)-hexaene-4,6,13-triol
C18H15N3O3S (353.0834080000001)
(3r,4r,5r,6r,10s)-4,6-dihydroxy-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,14(21),16-pentaen-13-one
C18H15N3O3S (353.0834080000001)
5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁵,²³.0¹⁶,²⁰]tetracosa-1(24),2(10),3,8,15,20,22-heptaene-3,14-diol
C19H15NO6 (353.08993300000003)
